Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Scott Stroup

Showing results (11-20 of 143) with videos related to

Pageof 15
Sort By:
Schizophrenia Research|August 6, 2019
Examination of heterogeneity in treatment response to antipsychotic medicationsNatalie Bareis, T Scott Stroup
Evidence-Based Mental Health|August 23, 2011
Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophreniaT Scott Stroup, L Fredrik Jarskog
Evidence-Based Mental Health|January 27, 2011
No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differT Scott Stroup, L Fredrik Jarskog
The American Journal of Psychiatry|September 30, 2003
Schizophrenia, VI: TreatmentsJeffrey A Lieberman, T Scott Stroup
Schizophrenia Bulletin|April 1, 2008
Paliperidone for treatment of schizophreniaAbraham M Nussbaum, T Scott Stroup
Schizophrenia Bulletin|November 12, 2005
Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia studyT Scott Stroup, Paul S Appelbaum
The New England Journal of Medicine|January 23, 2004
Schizophrenia, drug therapy, and monitoringDaniel W Bradford, T Scott Stroup
The American Journal of Psychiatry|August 5, 2011
The NIMH-CATIE Schizophrenia Study: what did we learn?Jeffrey A Lieberman, T Scott Stroup
Schizophrenia Bulletin|February 5, 2008
Randomized controlled trials for schizophrenia: study designs targeted to distinct goalsT Scott Stroup, John R Geddes
Schizophrenia Bulletin|September 12, 2012
Paliperidone palmitate for schizophreniaAbraham M Nussbaum, T Scott Stroup
Pageof 15

Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
Schizophrenia Research|August 6, 2019
Examination of heterogeneity in treatment response to antipsychotic medicationsNatalie Bareis, T Scott Stroup
Evidence-Based Mental Health|August 23, 2011
Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophreniaT Scott Stroup, L Fredrik Jarskog
Evidence-Based Mental Health|January 27, 2011
No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differT Scott Stroup, L Fredrik Jarskog
The American Journal of Psychiatry|September 30, 2003
Schizophrenia, VI: TreatmentsJeffrey A Lieberman, T Scott Stroup
Schizophrenia Bulletin|April 1, 2008
Paliperidone for treatment of schizophreniaAbraham M Nussbaum, T Scott Stroup
Schizophrenia Bulletin|November 12, 2005
Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia studyT Scott Stroup, Paul S Appelbaum
The New England Journal of Medicine|January 23, 2004
Schizophrenia, drug therapy, and monitoringDaniel W Bradford, T Scott Stroup
The American Journal of Psychiatry|August 5, 2011
The NIMH-CATIE Schizophrenia Study: what did we learn?Jeffrey A Lieberman, T Scott Stroup
Schizophrenia Bulletin|February 5, 2008
Randomized controlled trials for schizophrenia: study designs targeted to distinct goalsT Scott Stroup, John R Geddes
Schizophrenia Bulletin|September 12, 2012
Paliperidone palmitate for schizophreniaAbraham M Nussbaum, T Scott Stroup
Pageof 15